Market Overview

UPDATE: JP Morgan Upgrades MannKind to Neutral on Capitalization, Data Catalysts

Related MNKD
Analyst: MannKind Afrezza Estimates Are Being Changed 'Based On Physician Feedback'
Benzinga's Top #PreMarket Losers
Afrezza Could Be Sanofi And MannKind's Goose That Laid The Golden Egg (Seeking Alpha)

JP Morgan raised its rating on MannKind (NASDAQ: MNKD) from Underweight to Neutral as the company appears to have sufficient capital to complete ongoing pipeline trials.

JP Morgan noted, "MNKD's quarterly report was essentially a nonevent. However, we are incrementally more confident that the company's recent (and highly dilutive) offering should enable funding of the Phase 3 AFFINITY trials through data in mid 2013. We feel relatively comfortable with Afrezza's clinical outlook based on decent (some would say mixed) past Ph3 data. Longer term, we believe a partner will be needed to launch the drug, and while a deal could meaningfully de-risk the stock, we are skeptical that one will be secured prior to the Ph3 data (and potentially not even after). Thus our commercial concerns remain."

MannKind closed at $1.93 on Thursday.

Latest Ratings for MNKD

Mar 2015Goldman SachsDowngradesNeutralSell
Oct 2014Goldman SachsInitiates Coverage onNeutral
Aug 2014JefferiesInitiates Coverage onBuy

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (MNKD)

Around the Web, We're Loving...